Jensen, Maj-Britt http://orcid.org/0000-0001-5348-3040
Lænkholm, Anne-Vibeke
Balslev, Eva
Buckingham, Wesley
Ferree, Sean
Glavicic, Vesna
Dupont Jensen, Jeanette
Søegaard Knoop, Ann
Mouridsen, Henning T.
Nielsen, Dorte
Nielsen, Torsten O.
Ejlertsen, Bent
Funding for this research was provided by:
NanoString Technologies
Article History
Received: 27 September 2019
Accepted: 24 January 2020
First Online: 26 February 2020
Competing interests
: M.J. reports institutional research support from NanoString Technologies and Oncology Venture. A.V.L. reports institutional research support from NanoString Technologies. E.B., V.G., J.D.J., A.S.K., H.T.M., and D.N. declare no competing interests. W.B. has employment by NanoString Technologies. S.F. is an employee and Stockholder of NanoString Technologies. T.O.N. is an inventor on a patent (Perou CM, Parker JS, Marron JS, Nobel A, Bernard PS, Ellis M, Mardis E, Nielsen TO, Cheang M. Gene expression profiles to predict breast cancer outcomes) which has been issued by the European Patent Office (Patent Number 2297359) covering the PAM50 assay, which has been licensed to NanoString. T.O.N. has a consulting or advisory role with Bioclassifier LLC and Nanostring Technologies. B.E. reports institutional research support from NanoString Technologies, Roche, and Novartis.